BACKGROUND: The majority of patients with type 2 diabetes mellitus (T2DM) are overweight or obese. Obesity is a significant risk factor for increased morbidity and mortality in people with T2DM, and increased weight has been shown to worsen glycemic control and increase the risk of diabetes progression. METHODS: A search was conducted of the National Library of Medicine (PubMed) for articles published from 1990 to 2009 about the treatments of T2DM, relationship between T2DM and weight gain, obesity-related comorbidities of T2DM, and T2DM therapies associated with increased weight. Reference lists of retrieved articles were reviewed for additional publications. FINDINGS: Results from large, prospective clinical trials have shown that weight reduction significantly improves glycemic control and blood pressure in T2DM patients and lowers the risk of progression of T2DM as well as CV disease and cancer. Treatment-related weight gain is a side effect of many oral antidiabetes agents and insulin. The thiazolidinediones (TZD), sulfonylureas, and glinides are associated with weight gain. Despite the weight gain, TZDs also redistribute fat from the central to peripheral compartments, which may lead to a beneficial effect on insulin resistance. Among insulin products, the basal insulin analog detemir is typically associated with a smaller weight increase than human insulin and insulin analog preparations, including glargine, biphasic, and prandial insulin regimens. Alpha-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors are weight neutral, whereas glucagon-like peptide1-R agonists and metformin are associated with weight loss. DISCUSSION: An effective approach to management of the obese patient with diabetes is to communicate the significant benefits of a 1 kg reduction in body weight or prevention of weight gain on glycemic control and reduced morbidity and mortality. LIMITATION: This article is based on an extensive literature review rather than the prospective studies needed to define further the effect of weight gain on the management of T2DM. CONCLUSION: Weight management should be an integral part of a T2DM treatment strategy that includes selecting oral antidiabetes medications and insulin products that are weight beneficial.
BACKGROUND: The majority of patients with type 2 diabetes mellitus (T2DM) are overweight or obese. Obesity is a significant risk factor for increased morbidity and mortality in people with T2DM, and increased weight has been shown to worsen glycemic control and increase the risk of diabetes progression. METHODS: A search was conducted of the National Library of Medicine (PubMed) for articles published from 1990 to 2009 about the treatments of T2DM, relationship between T2DM and weight gain, obesity-related comorbidities of T2DM, and T2DM therapies associated with increased weight. Reference lists of retrieved articles were reviewed for additional publications. FINDINGS: Results from large, prospective clinical trials have shown that weight reduction significantly improves glycemic control and blood pressure in T2DM patients and lowers the risk of progression of T2DM as well as CV disease and cancer. Treatment-related weight gain is a side effect of many oral antidiabetes agents and insulin. The thiazolidinediones (TZD), sulfonylureas, and glinides are associated with weight gain. Despite the weight gain, TZDs also redistribute fat from the central to peripheral compartments, which may lead to a beneficial effect on insulin resistance. Among insulin products, the basal insulin analog detemir is typically associated with a smaller weight increase than humaninsulin and insulin analog preparations, including glargine, biphasic, and prandial insulin regimens. Alpha-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors are weight neutral, whereas glucagon-like peptide1-R agonists and metformin are associated with weight loss. DISCUSSION: An effective approach to management of the obesepatient with diabetes is to communicate the significant benefits of a 1 kg reduction in body weight or prevention of weight gain on glycemic control and reduced morbidity and mortality. LIMITATION: This article is based on an extensive literature review rather than the prospective studies needed to define further the effect of weight gain on the management of T2DM. CONCLUSION: Weight management should be an integral part of a T2DM treatment strategy that includes selecting oral antidiabetes medications and insulin products that are weight beneficial.
Authors: Sarah A Purcell; Sarah A Elliott; Peter J Walter; Tom Preston; Hongyi Cai; Richard J E Skipworth; Michael B Sawyer; Carla M Prado Journal: Am J Clin Nutr Date: 2019-08-01 Impact factor: 7.045
Authors: Matthew J Crowley; David Edelman; Corrine I Voils; Matthew L Maciejewski; Cynthia J Coffman; Amy S Jeffreys; Marsha J Turner; Leslie A Gaillard; Teresa A Hinton; Elizabeth Strawbridge; Jennifer Zervakis; Anna Beth Barton; William S Yancy Journal: Contemp Clin Trials Date: 2017-04-23 Impact factor: 2.226
Authors: Leslea Peirson; James Douketis; Donna Ciliska; Donna Fitzpatrick-Lewis; Muhammad Usman Ali; Parminder Raina Journal: CMAJ Open Date: 2014-10-01
Authors: Nathan D Wong; Christopher Patao; Kalina Wong; Shaista Malik; Stanley S Franklin; Uchenna Iloeje Journal: Diab Vasc Dis Res Date: 2013-08-22 Impact factor: 3.291
Authors: F Zurlo; C Trevisan; N Vitturi; E Ravussin; C Salvò; S Carraro; M Siffi; I Iob; A Saller; L Previato; G Sergi; S de Kreutzenberg; A Maran; A Avogaro Journal: J Endocrinol Invest Date: 2019-07-29 Impact factor: 4.256